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Abstract: Despite the clinical benefits of lowering levels of low-density lipoprotein cholesterol, 
many patients continue to experience cardiovascular events. This residual risk suggests that 
additional risk factors require aggressive modification to result in more effective prevention 
of cardiovascular disease. Hypertriglyceridemia has presented a considerable challenge with 
regard to understanding its role in the promotion of cardiovascular risk. Increasing evidence has 
established a clear causal role for elevated triglyceride levels in vascular risk. As a result, there 
is increasing interest in the development of specific therapeutic strategies that directly target 
hypertriglyceridemia. This has seen a resurgence in the use of omega-3 fatty acids for the thera-
peutic lowering of triglyceride levels. The role of these agents and other emerging strategies to 
reduce triglyceride levels in order to decrease vascular risk are reviewed.
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Introduction
The role of low-density lipoprotein cholesterol (LDL-C) in cardiovascular disease is 
well established, with LDL-C lowering being the cornerstone of preventive strategies. 
This is evidenced from statin trials, in which the degree of LDL-C lowering directly 
associated with their clinical benefit.1 However, many cardiovascular events continue 
to occur even in patients who achieve low LDL-C levels, reflecting a substantial 
residual risk.2 In the search to identify factors associated with persistent cardiovas-
cular risk, it is clear that LDL-C alone does not fully reflect the circulating burden of 
atherogenic lipoproteins. In particular, triglyceride-rich particles (very low-density 
lipoproteins [VLDL], intermediate density lipoproteins, chylomicrons) play an 
important role in the promotion of the atherosclerotic disease process and are poorly 
reflected by conventional LDL-C measures. It is therefore not surprising that levels 
of non-high-density lipoprotein cholesterol (non-HDL-C), which reflect the entire 
burden of atherogenic lipid particles, associate with vascular risk and have become 
increasingly used as a secondary target for modification in treatment guidelines.3 As 
the incidence of abdominal obesity, metabolic syndrome, and type 2 diabetes mellitus 
rises, associated triglyceride-rich lipoproteins are likely to have a greater impact on 
promoting vascular risk.4
Population studies of hypertriglyceridemia  
and cardiovascular risk
Elevated triglyceride levels have become increasingly prevalent in the community. 
Follow-up of the National Health and Nutrition Examination Survey has found that 





32.2% of individuals have elevated triglyceride levels, 
including 1.7% with levels considered severe (500–
2,000 mg/dL).5 While early studies failed to convincingly 
establish an association between triglyceride levels and 
cardiovascular disease, more recent data, including cohort 
studies and meta-analyses, have shown that increases in both 
fasting and nonfasting triglyceride levels directly associate 
with cardiovascular risk.
Further analysis has revealed that the strength of the 
association between triglyceride levels and cardiovascular 
risk may differ between males and females, with evidence 
that each 1 mmol/L increase in triglyceride associates with a 
32% and 76% increase in risk, respectively. While the degree 
of this association is attenuated after controlling for other 
metabolic risk factors, a greater impact in females continues 
to be observed.6 In clinical trials of statins, elevated triglycer-
ide levels identify patients at a higher risk of cardiovascular 
events, despite use of high-intensity statin therapy.7
Generation of triglyceride-rich 
lipoproteins
Hypertriglyceridemia results from a number of sources, 
including dietary fat consumption and generation of chylo-
micron and remnant particles, hepatic synthesis of VLDL, 
and impaired metabolic clearance of these particles from the 
circulation. Triglyceride-rich lipoproteins undergo hydrolysis 
by lipoprotein lipase within capillary beds in adipose, car-
diac, and skeletal muscle tissue beds to release nonesterified 
fatty acids for local use, generating remnant particles within 
the systemic circulation. These remnant particles, specifi-
cally VLDL remnants, contain substantial cholesterol due 
to increased activity of cholesteryl ester transfer protein in 
hypertriglyceridemia favoring transfer to VLDL rather than 
LDL particles.8 Reduced size of these remnant particles 
renders them more likely to enter and be retained within the 
artery wall.9,10 In this location, they play a significant role 
in formation of foam cells, the major cellular component of 
the evolving atherosclerotic plaque.11,12
Apolipoprotein C (apoC)-III resides on VLDL, LDL, 
chylomicrons, and HDL particles within the circulation. 
Increased apoC-III production is a characteristic feature of 
patients with insulin resistance and hypertriglyceridemia, by 
virtue of its role in the inhibition of lipolytic activity13 and 
hepatic uptake of triglyceride-rich lipoproteins. Increasing 
evidence implicates apoC-III in the promotion of inflam-
matory pathways within the artery wall, suggesting that it 
may influence atherogenesis via lipid-mediated and lipid-
independent processes.14 Further evidence that these factors 
involved in the metabolism of triglyceride-rich lipoproteins 
play an important role in atherosclerosis comes from genomic 




The initial effort to lower triglyceride levels should begin 
with lifestyle modification and improved glycemic control 
in diabetes, with evidence that these measures can have 
rapid and profound beneficial effects. Weight loss is associ-
ated with consistent reductions in triglyceride levels across 
multiple studies and is an essential part of treatment for 
hypertriglyceridemia.18–21 The relative impact of specific 
diets and exercise regimens on achieving weight loss has had 
variable reports with regard to their effects on triglyceride 
levels.
High-fat content diets lead to obesity and increased vis-
ceral adiposity, which is associated with insulin  resistance. 
While a low-fat diet would intuitively seem the best dietary 
approach, there are some reports that comparisons of 
moderate-fat content diets with low-fat diets actually show 
that moderate fat intake elicits a more favorable effect on 
triglyceride levels.22 High-carbohydrate diets are associated 
with increased fatty liver changes,23 which are associated with 
increased hepatic triglyceride-rich lipoprotein production in 
proportion to the degree of liver fat.24 Low-carbohydrate diets 
consistently lower triglycerides, more so in those with higher 
baseline levels,25 and when integrated within Mediterranean 
diets appear to be superior in their triglyceride-lowering 
effect than low-fat diets.26
Exercise increases lipoprotein lipase activity27 with mod-
est triglyceride lowering.28 While smoking cessation can 
often be associated with weight gain, its benefit in terms of 
triglyceride lowering is still evident, given the association 
of insulin resistance and postprandial hypertriglyceridemia 
in smokers.29 There appears to be a U-shaped relationship 
between amount of alcohol intake and triglyceride levels, so 
hypertriglyceridemic patients should be encouraged to only 
drink alcohol in moderation.30 For patients presenting with 
marked hypertriglyceridemia, cessation of alcohol consump-
tion, restriction of dietary fat intake, and more aggressive 
glycemic control in diabetic patients can each have a rapid 
and profound effect on triglyceride levels.
Statins
Statins lower triglycerides in a dose-dependent manner, par-
ticularly in the hypertriglyceridemia patient.31,32 Given their 





benefit in terms of cardiovascular event rate reduction, 
treatment guidelines recommend intensification of LDL-C 
lowering with statins as the first pharmacological treatment 
choice in hypertriglyceridemic patients. The persistence of 
elevated triglyceride levels identifies patients with a residual 
clinical risk in statin trials, suggesting an ongoing need to 
develop additional therapeutic strategies for these patients.
Fibrates
Fibrates are modest pharmacological agonists of peroxisome 
proliferator-activated receptor-α (PPAR-α), a transcription 
factor and major regulator of lipid metabolism. Their major 
influences on plasma lipids include reducing triglycerides 
and increasing HDL cholesterol. Their lipid effects appear 
to be mediated by a reduction in apoC-III expression and 
increases in lipoprotein lipase activity, hepatic synthesis of 
the major apolipoproteins (apoA-I, apoA-II) carried on HDL 
particles, and oxidation of fatty acids, which in turn lead to 
a decrease in the rate of hepatic lipogenesis.33 While studies 
have shown that fibrates retard progression of angiographic 
disease,34,35 the major clinical outcome trials of fibrates have 
demonstrated variable effects on cardiovascular events. 
While studies of gemfibrozil have demonstrated a favorable 
effect,36,37 it can be difficult to administer in combination with 
statin therapy. More recent studies of fenofibrate in statin-
treated patients with diabetes failed to demonstrate a benefit 
in terms of the primary endpoint,38,39 although subsequent 
analyses have shown a favorable impact on hard clinical 
endpoints (death, myocardial infarction, stroke)39 in patients 
with a prior myocardial infarction40 and on the microvascular 
complications of diabetes.41 While triglyceride lowering does 
not appear to contribute to any potential benefit of fibrate 
therapy, meta-analyses have demonstrated that it is the patient 
with elevated triglyceride levels at baseline in whom they are 
most likely to be protective.42 Recent attempts to develop 
more potent PPAR-α43 and dual PPAR-α/γ agonists44 have 
failed to demonstrate incremental efficacy and have raised 
additional safety concerns.
Niacin
Niacin has a range of lipid-modifying effects, including 
substantial raising of HDL-C in addition to lowering of 
triglycerides, LDL-C, and lipoprotein(a).45 While the mecha-
nism underlying its lipid effects remains to fully elucidated, 
triglyceride lowering is likely to result from inhibition of 
diacylglycerol acyltransferase 2.46 Early trials prior to the use 
of statins demonstrated reductions in cardiovascular events 
in survivors of myocardial infarction with immediate-release 
formulations of niacin administered as monotherapy47 and 
in combination with clofibrate.48 Subsequent arterial wall 
imaging studies have demonstrated that niacin has a favorable 
impact on progression of atherosclerotic disease within the 
coronary and carotid vasculature.49–52 However, niacin use is 
limited by near ubiquitous experience of flushing mediated by 
prostaglandin-mediated vasodilation. This prevents appropri-
ate dose escalation required to achieve lipid effects. Multiple 
efforts have been undertaken to improve tolerance of niacin, 
including use of extended-release formulations and admin-
istration in combination with a selective  prostaglandin-2 
receptor inhibitor, laropiprant. However, clinical trials of 
these approaches in statin-treated patients have not demon-
strated clinical efficacy, suggesting that niacin is not likely 
to be a widely used approach for lipid modification moving 
forward.53,54
Omega-3 fatty acids  
in hypertriglyceridemia
Considerable data, ranging from studies of fish consump-
tion in populations through to supplementation studies 
have consistently demonstrated that omega-3 (n-3) fatty 
acids lower triglyceride levels by 10%–30% in patients 
with hypertriglyceridemia, depending on the amount of n-3 
fatty acid administered and the baseline triglyceride level.55 
The major n-3 fatty acids, eicasopentaenoic acid (EPA) and 
docasohexaenoic acid (DHA), modulate each of the major 
nuclear receptors that regulate triglyceride levels, including 
liver X receptor (LXR), farnesol X receptor (FXR), hepato-
cyte nuclear factor-4α, and PPAR α, β, and γ.
These receptors play an important role in regulation 
of triglyceride-rich lipoproteins and therefore present a 
target for therapeutic modification by n-3 fatty acids. LXR 
regulates expression of sterol regulatory element-binding 
protein-1c (SREBP-1c), which plays a major role in tran-
scription of fatty acid-synthesizing enzymes. The n-3 fatty 
acids inhibit LXR from binding to the LXR response 
element and reducing SREBP-1c transcription56 and act 
directly on SREBP-1c, inhibiting its maturation.57 FXR 
plays a regulatory role in the enterohepatic circulation of 
lipids, with it binding and being activated by several bile 
acids, with stimulation increasing expression of short 
heterodimer protein, which via heterodimerization has 
multiple effects on bile acid and triglyceride homeostasis, 
including reducing expression of cholesterol-7-hydroxylase, 
the enzyme that regulates cholesterol catabolism into bile 
acids, reducing transcription of SREBP-1c, upregulating 
expression of PPAR-α, and decreasing hepatic secretion of 





triglyceride-containing lipoproteins.58,59 The n-3 fatty acids, 
via their FXR interaction, can differentially regulate expres-
sion of FXR targets.60 While n-3 fatty acids interact with all 
PPAR species, they have a clear preference for the α-subtype,61 
decreasing triglycerides in a similar fashion to fibrates. Hepa-
tocyte nuclear factor-α has multiple important roles in hepatic 
regulation of lipid metabolism, carbohydrate metabolism, 
hematopoiesis, and blood  coagulation. It plays an important 
role in the regulation of hepatic expression of apolipoproteins 
(A-I, A-II, B, C-II, C-III) and microsomal transfer protein. 
n-3 fatty acid stimulation of hepatocyte nuclear factor-α leads 
to a reduction of apoC-III  expression.62 EPA, but not DHA, 
inhibits activity of diacylglycerol acyltransferase, an enzyme 
that regulates the terminal and rate-limiting step of hepatic 
triglyceride synthesis.63 Accordingly, n-3 fatty acids play an 
important and diverse role in influencing a range of factors 
implicated in the regulation of triglyceride levels.
Prescription n-3 fatty  
acid formulations
A range of over-the-counter preparations of n-3 fatty acids, 
often under the label of fish oil, are widely used in popula-
tion for a range of indications, including lowering of plasma 
triglyceride levels. However, the finding that large doses 
of EPA and DHA, in the range of 3–4 g daily, are often 
required to produce meaningful triglyceride lowering in 
hypertriglyceridemic patients, presents a challenge for the 
use of many of these preparations. The actual content of 
EPA and DHA in over-the-counter preparations is often low, 
requiring individuals to consume large numbers of capsules 
on a daily basis (often up to 12 daily) to achieve effective 
triglyceride lowering. Such findings have led to the produc-
tion of pharmaceutical grade n-3 fatty acids with much higher 
concentrations (85% of their content were ethyl esters of EPA 
and DHA in comparison with most standard fish oil prepara-
tions containing 18% EPA and 12% DHA).64
The first prescription n-3 fatty acid preparation (Lovaza®, 
initially marketed as Omacor®) approved for use as an adjunct 
to diet in the treatment of severe hypertriglyceridemia con-
tained more than 90% of n-3 fatty acid ethyl esters (465 mg 
EPA, 375 mg DHA). Administration for up to 24 weeks 
in patients with severe hypertriglyceridemia demonstrated 
reductions in triglyceride levels by 19%–47%.65 In paral-
lel, early observations of increases in LDL-C levels were 
reported, the extent of which depended on the baseline trig-
lyceride level.66 It remains unknown whether this increase in 
LDL-C might have an adverse effect on the artery wall. It has 
been postulated by some that DHA plays a more prominent 
role in LDL-C elevation, with meta-analyses of both indi-
vidual and comparative studies revealing increases in LDL-C 
in 75% of DHA-treated and 40% of EPA-treated patients.67 
While the mechanism for the LDL-C increase remains to 
be fully elucidated, it has been proposed that this is likely 
to involve accelerated conversion of VLDL to intermediate 
density lipoprotein and LDL particles.68
Icosapent
Icosapent is the first EPA only prescription n-3 fatty acid 
(containing 96% of the ethyl ester of EPA) to receive regula-
tory approval. It undergoes de-esterification during intestinal 
absorption and enters the systemic circulation via the thoracic 
duct, achieving its peak plasma concentration 5 hours following 
ingestion. Icosapent is .99% protein bound in the plasma, has 
a volume of distribution of 88 liters, and displays predictable 
linear pharmacokinetics. It is currently approved for use as an 
adjunct to diet to reduce tri glyceride levels in adult patients with 
severe ($500 mg/dL)  hypertriglyceridemia. There are ongoing 
studies assessing its efficacy in reducing the risk of cardiovas-
cular events in high-risk patients with mixed dyslipidemia.
A multicenter, placebo-controlled, randomized, double-
blind 12-week study with an open-label extension (MARINE)69 
was conducted in patients with very high triglyceride levels, 
with randomization to either 2 g or 4 g daily of icosapent or 
placebo for 12 weeks. The treatment period was preceded by 
a 4–6-week run-in period, where subjects were counseled on 
a lifestyle changes diet to comply with throughout the trial. 
 Subjects with triglyceride levels of between 500 mg/dL and 
2,000 mg/dL following the run-in period qualified for random-
ization. The major exclusion criteria included supermorbid 
obesity (body mass index .45 kg/m2), poorly controlled dia-
betes, uncontrolled thyroid disease, nephritic syndrome range 
proteinuria (.3 g/day), and heavy alcohol intake. Twenty-five 
percent of the subjects included in the randomization were 
treated with a statin. Significant placebo-adjusted reduc-
tions in triglycerides were observed in both the 4 g (-33.1%, 
P,0.0001) and 2 g (-19.7%, P=0.005) groups. In those indi-
viduals with baseline triglyceride levels .750 mg/dL, greater 
reductions were observed in the 4 g (-45.4%, P=0.0001) and 
2 g (-32.9%, P=0.002) groups. Associated reductions in 
non-HDL-C, VLDL, and lipoprotein phospholipase A2 were 
also observed, with greater effects noted in the 4 g group. 
Significant LDL-C elevations were not observed in this study, 
although the exploratory analysis was underpowered. Icosap-
ent was well tolerated, with similar rates of adverse events 
(most commonly nausea, diarrhea, and eructation) observed 
in both groups.





The ANCHOR study70 was a randomized, double-blind, 
placebo-controlled study of patients with a high cardiovascu-
lar disease risk and adequate LDL-C control (40–115 mg/dL) 
with statins ± ezetimibe, but with high triglyceride levels 
(185–500 mg/dL). A total of 702 patients were randomized 
to 2 g or 4 g of icosapent or placebo daily for a 12-week treat-
ment period, following a run-in period similar to that of the 
MARINE study. The study included a prespecified analysis to 
demonstrate noninferiority of LDL-C change compared with 
placebo. The key exclusion criteria for the trial were super-
morbid obese patients with a body mass index .45 kg/m2, 
poorly controlled diabetics, and subjects treated with fibrates 
or niacin. Significant reductions in triglyceride levels were 
observed in both the 4 g (-21.5%, P,0.0001) and 2 g 
(-10.1%, P=0.0005) groups. Similar reductions in associated 
lipoproteins were observed as reported in MARINE, with 
the additional finding of a significant reduction in C-reactive 
protein in the 4 g group. Noninferiority compared with pla-
cebo with regards to LDL-C changes was observed in both 
active treatment groups. Icosapent was well tolerated, with 
similar adverse event and discontinuation rates reported in 
all three treatment groups.
Outcome trials with ePA
JELIS (the Japan EPA Lipid Intervention Study) was a 
prospective, randomized, open-label, blinded endpoint trial 
of 18,645 patients with elevated serum total cholesterol 
($250 mg/dL), but notably relatively normal triglyceride lev-
els, treated with EPA 1.8 g or placebo daily in addition to statin 
therapy. Treatment with EPA was associated with a greater 
lowering of triglycerides (-9% versus -4%, P,0.0001) and a 
19% reduction in the composite primary endpoint of any major 
coronary event, including sudden cardiac death, fatal or nonfa-
tal myocardial infarction and nonfatal events, unstable angina 
pectoris, or need for coronary revascularization. Subsequent 
analyses revealed that EPA reduced cardiovascular events by 
53% in patients with evidence of atherogenic dyslipidemia at 
baseline (triglycerides .150 mg/dL, HDL-C ,40 mg/dL).71,72 
Of particular interest, these findings were observed in a study 
performed exclusively in Japan, where the doses of background 
statin therapy were low, the dose of EPA was relatively modest, 
and general consumption of fish is higher. Accordingly, it is of 
interest to know whether similar findings could be observed 
in Western populations.
ReDUCe-iT
REDUCE-IT is a multicenter, multinational, prospec-
tive, randomized, double-blind, placebo-controlled, 
 parallel-group study of patients aged $45 years and at high 
risk for cardiovascular events, with elevated triglyceride levels 
(150–500 mg/dL) despite optimized statin therapy. Subjects 
will be randomized to treatment with icosapent 4 g or placebo 
daily. Treatment groups will be compared with regard to the 
incidence of cardiovascular death, nonfatal myocardial infarc-
tion, nonfatal stroke, coronary revascularization, and unstable 
angina determined to be caused by myocardial ischemia 
on invasive or noninvasive testing and requiring emergent 
 hospitalization. This will determine whether high-dose admin-
istration of EPA has a cardiovascular benefit in high-risk 
statin-treated patients with modest hypertriglyceridemia.
Conclusion
Hypertriglyceridemia at severe levels is an important risk 
factor for pancreatitis, and persistently high triglyceride 
levels despite optimal LDL-C control conveys increased 
residual risk of cardiovascular disease. There is a clear need 
for a therapeutic option in hypertriglyceridemia that can 
be used in addition to statin therapy to further reduce the 
cardiovascular disease risk and burden. Icosapent shows 
clear benefit in the treatment of severe hypertriglyceridemia 
and has also shown efficacy in the treatment of patients 
with more moderate elevations in serum triglyceride levels 
already treated with statins. However, favorable effects on 
lipid biomarkers, particularly those beyond LDL-C, have 
not been easily demonstrated to translate to a beneficial 
effect on cardiovascular events. Accordingly, the result of 
REDUCE-IT will be eagerly awaited to determine whether 
icosapent will be widely used or remain as a treatment for 
severe hypertriglyceridemia alone.
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